The Latest Cardiac and Vascular News
Anticipated New Patent Will Add to the Istaroxime Patent Estate and Provide Intellectual Property Protection Until Late 2039 WARRINGTON, Pa., Oct. 25, 2022 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular disorders, today reported that the United States Patent […]
WARRINGTON, Pa., Sept. 28, 2022 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular disorders, today reported that the results of its positive Phase 2 istaroxime study in early cardiogenic shock were published in the European Journal of Heart Failure (https://doi.org/10.1002/ejhf.2629). […]
WARRINGTON, Pa., Sept. 26, 2022 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular disorders, today reported that a late breaking abstract describing dose response data from its positive Phase 2 clinical study of istaroxime in early cardiogenic shock […]
WARRINGTON, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the second quarter ended June 30, 2022 and provided key business updates. “Since announcing the positive topline results from […]
Announced positive topline results from Phase 2 SEISMiC study of istaroxime in early cardiogenic shock Late-breaker presentation of additional SEISMiC study results at the European Society of Cardiology (ESC) Heart Failure Conference. Management to host investor call following the presentation on May 23 WARRINGTON, Pa., May 05, 2022 (GLOBE NEWSWIRE) […]
Istaroxime significantly improved the systolic blood pressure profile WARRINGTON, Pa., April 20, 2022 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced positive primary results with istaroxime in rapidly raising systolic blood pressure, the […]
WARRINGTON, Pa., March 31, 2022 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided key business updates. “This past quarter […]
WARRINGTON, Pa., May 13, 2021 /PRNewswire/ — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the first quarter ended March 31, 2021 and provided key business updates. Key Business and Financial Updates Expanded the participating […]
WARRINGTON, Pa., March 29, 2021 /PRNewswire/ — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the fourth quarter and year ended December 30, 2020 and provided key business updates. Key Business and Financial Updates Completed […]
WARRINGTON, Pa., Nov. 16, 2020 /PRNewswire/ — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the third quarter ended September 30, 2020 and provided key business updates. Key Business and Financial Updates Announced the dosing […]
